PamGene Licenses Its Microarray Platform to the University of Nottingham
Den Bosch, The Netherlands. PamGene International BV has today announced the licensing of its 3-Dimensional, Flow-Through Microarray Platform to Nottingham University, England. This service licence, which includes the sale of a PamGene 4-array PamStation(TM) will enable the University to develop Multiplex Amplifiable Probe Hybridization (MAPH) as a service on the PamGene platform.
MAPH, originally developed by Dr John Armour of Nottingham University, can quickly and accurately determine copy number changes in genomic DNA. Such changes are known to play a role in the generation of a number of diseases including breast cancer, colon cancer and muscular dystrophy. The University's Institute of Genetics, where the PamStation(TM) is to be based, will now have the ability to automate their MAPH tests in a microarray format, using the 30-minute hybridisation procedure offered by PamGene's 3-dimensional flow-through microarray technology.
'This will be a very useful system whereby we can exploit the MAPH technology further for detecting deletions and duplications in genomic DNA. It will also allow the potential to screen all copy number changes in the human genome at a resolution of 1-10Mb in a rapid manner", explained Dr Armour.
Although the PamGene system will initially be used for internal MAPH research, a service will be offered in the near future through a new company to be spun out of The University's Institute of Genetics. The University also intends to use the instrument, specifically designed for PamChip(R) Arrays, as a centralised service system for focused microarray analysis.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Every single cell counts - even before birth! - Certain immune cells develop early in life and remain throughout life
Tripos to Build One of the Leading Informatics-Driven Drug Discovery Laboratories in Europe - - State-of-the-Art Chemical Synthesis Facilities to be Built in Cornwall, England -
Recipharm goes ‘green’ with environmental management system - Recipharm’s Wasserburg facility achieves ISO 14001 and OHS&S 18001 standards
ChEBI
Crotalus_totonacus
Innogenetics partners with PamGene to develop its new generation multi parameter diagnostic platform
Gum_graft
Crotalus_molossus
Swapsc

New Endoscopic Technique - Flexible wide-field endoscope provides label-free contrast of tissue based on fluorescence lifetime imaging of tissue autofluorescence
